Skip to navigation Skip to content

Clinical Trial: Fingolimod

Share

Details
Type of MS: RRMS|SPMS
Treatment mode of action: To affect immune function.
Number of Subjects: 30
Medication: Fingolimod or treated with another approved disease-modifying therapy and switched to fingolimod
Location: Georgia
Institutions:

Agile Clinical Research Trials

Contact Information
Ms. Windy Thomas
404-400-2255
wendy@agilecrt.com

Funding:

Novartis

Description

Patients with relapsing forms of multiple sclerosis either newly treated with fingolimod or treated with another approved disease-modifying therapy and switched to fingolimod.

Share